{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:35:38Z","timestamp":1791117338792,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,9,29]],"date-time":"2007-09-29T00:00:00Z","timestamp":1191024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2007,11,12]]},"DOI":"10.1007\/s00345-007-0212-5","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T07:41:41Z","timestamp":1190965301000},"page":"627-633","source":"Crossref","is-referenced-by-count":33,"title":["Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia"],"prefix":"10.1007","volume":"25","author":[{"given":"K.","family":"H\u00f6fner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,29]]},"reference":[{"key":"212_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61:37\u201349","journal-title":"Urology"},{"key":"212_CR3","unstructured":"Abrams P, Cardozo L, Khoury S et al (2005) Incontinence. Management, vol 2. Health Publication Ltd, Plymouth"},{"key":"212_CR4","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","volume":"169","author":"A Athanasopoulos","year":"2003","unstructured":"Athanasopoulos A, Gyftopoulos K, Giannitsas K et al (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169:2253\u20132256","journal-title":"J Urol"},{"key":"212_CR5","doi-asserted-by":"crossref","unstructured":"Barry MJ, Fowler FJ Jr, O\u2019Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549\u20131557, discussion 1564","DOI":"10.1016\/S0022-5347(17)36966-5"},{"key":"212_CR1","unstructured":"Cockett ATK AY, Chatelain C et al (1991) Recommendations of the International Consensus Committee. In: Cockett ATK AY, Chatelain C et al (eds) Proceedings of the international consultation on benign prostatic hyperplasia (BPH). Paris, pp 279\u2013288"},{"key":"212_CR6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","volume":"11","author":"K Coyne","year":"2002","unstructured":"Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563\u2013574","journal-title":"Qual Life Res"},{"issue":"6","key":"212_CR7","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1016\/S1098-3015(10)67167-7","volume":"8","author":"KS Coyne","year":"2005","unstructured":"Coyne KS, Matza L, Kopp Z et al (2005) Determining the minimally important difference of the overactive bladder questionnaire (OAB-q). Value Health 8(6):A9","journal-title":"Value Health"},{"key":"212_CR8","doi-asserted-by":"crossref","unstructured":"Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174:2273\u20132275, discussion 2275\u20132276","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"key":"212_CR9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00002018-200124090-00005","volume":"24","author":"D Layton","year":"2001","unstructured":"Layton D, Pearce GL, Shakir SA (2001) Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 24:703\u2013713","journal-title":"Drug Saf"},{"key":"212_CR10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","volume":"94","author":"JY Lee","year":"2004","unstructured":"Lee JY, Kim HW, Lee SJ et al (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817\u2013820","journal-title":"BJU Int"},{"key":"212_CR11","unstructured":"Lim E, Chia SJ (2005) Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? International Continence Society ICS, Montreal. http:\/\/www.continet.org\/publications\/2005\/pdf\/0205.pdf"},{"key":"212_CR12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2004.07.016","volume":"46","author":"S Madersbacher","year":"2004","unstructured":"Madersbacher S, Alivizatos G, Nordling J et al (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547\u2013554","journal-title":"Eur Urol"},{"key":"212_CR13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398","journal-title":"N Engl J Med"},{"key":"212_CR14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5347(05)68563-1","volume":"162","author":"JB Meigs","year":"1999","unstructured":"Meigs JB, Barry MJ, Giovannucci E et al (1999) Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 162:376\u2013382","journal-title":"J Urol"},{"key":"212_CR15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.ju.0000130580.82989.d6","volume":"172","author":"MC Michel","year":"2004","unstructured":"Michel MC, de la Rosette JJ, Piro M et al (2004) Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 172:601\u2013604","journal-title":"J Urol"},{"key":"212_CR16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0022-5347(01)62787-3","volume":"160","author":"MC Michel","year":"1998","unstructured":"Michel MC, Mehlburger L, Bressel HU et al (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160:784\u2013791","journal-title":"J Urol"},{"key":"212_CR17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","volume":"168","author":"MC Michel","year":"2002","unstructured":"Michel MC, Schneider T, Krege S et al (2002) Does gender or age affect the efficacy and safety of tolterodine? J Urol 168:1027\u20131031","journal-title":"J Urol"},{"key":"212_CR18","unstructured":"Okada H, Shirakawa T, Muto S et al (2004) Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. J Urol 171 (Suppl):abstract 1358"},{"key":"212_CR19","unstructured":"Hartung J (1993) Statistik, Lehr- und Handbuch der angewandten Statistik. 9th edn. Oldenbourg, M\u00fcnchen Wien, p 204"},{"key":"212_CR20","doi-asserted-by":"crossref","unstructured":"Rackley R, Weiss J, Rovner ES et al (2007) Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology (in press)","DOI":"10.1016\/j.urology.2005.10.061"},{"key":"212_CR21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/01.ju.0000112918.74410.94","volume":"171","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG, Bruskewitz R, Nickel JC et al (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6\u00a0years in men with benign prostatic hyperplasia. J Urol 171:1194\u20131198","journal-title":"J Urol"},{"key":"212_CR22","unstructured":"Roehrborn CG, McConnell JD, Barry MJ et al (2003) AUA guideline on the management of benign prostatic hyperplasia. http:\/\/www.auanet.org\/timssnet\/products\/guidelines\/main_reports\/bph_management\/preface_toc.pdf"},{"key":"212_CR23","first-page":"525","volume":"12","author":"H Saito","year":"1999","unstructured":"Saito H, Yamada T, Oshima H et al (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin in the benign prostatic hypertrophy with pollakiuria and\/or urinary incontinence. Jpn J Urol Surg 12:525\u2013536","journal-title":"Jpn J Urol Surg"},{"key":"212_CR24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/nau.10053","volume":"21","author":"P Kerrebroeck van","year":"2002","unstructured":"van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179\u2013183","journal-title":"Neurourol Urodyn"},{"key":"212_CR25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2004.11.011","volume":"47","author":"KM Verhamme","year":"2005","unstructured":"Verhamme KM, Dieleman JP, van Wijk MA et al (2005) Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47:494\u2013498","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-007-0212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-007-0212-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-007-0212-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:35:40Z","timestamp":1559050540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-007-0212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,29]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,11,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s00345-007-0212-5","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,29]]}}}